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Abstract
Background: In many countries exercise prescriptions are used in an attempt to initiate a
physically active lifestyle in sedentary populations. Previous studies have primarily evaluated low
intensive exercise prescription interventions and found moderately positive effects on physical
activity and aerobic fitness. In a highly intensive Danish exercise prescription scheme called
'Exercise on Prescription' (EoP) the general practitioners can prescribe EoP to sedentary patients
with lifestyle diseases. The aim of this randomized trial is to assess the short- and long-term effects
of the EoP scheme. Thus, the aim of this paper is to describe the randomized controlled trial
designed for evaluating effectiveness of EoP, and to present results from validations of outcome
measures.
Methods/Design: EoP involves a 16-week supervised training intervention and five counselling
sessions (health profiles). All patients referred to EoP were eligible for the trial and were offered
participation during the baseline health profile. Comparisons between the EoP group and the
control group were made at baseline, and after four and ten months. Physiological measures used
were maximal oxygen uptake (VO2max), glycosylated haemoglobin (HbA1c), bodyweight, and BMI.
Patient-reported measures used were physical activity, health-related quality of life, amount and
intensity of exercise, compliance with national guidelines for physical activity, and physical fitness.
The validation of the cycle ergometer test found a strong correlation between maximal work
capacity and VO2max, and acceptable test-retest reliability at group level. Calibration of the HbA1c
apparatus was stable over ten weeks with minimal use, and test-retest reliability was good. High
agreement percents were found for test-retest reliability for the self-administered questionnaire.
Discussion: The trial is designed to provide information about the effectiveness of the EoP
scheme. The trial is part of a health technology assessment of EoP, which besides the effectiveness
covers the patient perspective, the organization, and the health economy. All three methods
validated were found useful for the EoP trial.
Background
Epidemiological studies have reported a reduced risk of
lifestyle diseases and/or mortality with increased level of
physical activity [1] and aerobic fitness [2]. A physically
active lifestyle is recommended both as part of treatment,
prevention and rehabilitation with regard to a number of
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benefits of a physically active lifestyle, large parts of the
population remain physically inactive, posing a serious
threat to public health [4,5].
In many countries exercise prescriptions are used in an
attempt to initiate a physically active lifestyle in sedentary
populations. However, a recent population-based analysis
questions the impact of exercise prescriptions on
increased physical activity at population level [6], and a
population-based survey reports that general practitioners
(GPs) give physical activity advice and exercise prescrip-
tion to only 13 % and 3 %, respectively [7]. Furthermore,
a recent review concludes that exercise prescriptions only
have a moderately positive effect on physical activity level
and aerobic fitness [8]. However, exercise prescriptions
are still used extensively [9]. Most exercise prescription
studies have evaluated GP counselling in combination
with low intensive interventions (e.g. possibility to see an
exercise specialist [10], pedometers and exercise logs [10],
community-based activities and telephone support [11],
access to local physical activity facilities and leisure cen-
tres [12], telephone booster calls [13], and stage-matched
written material [14]). Few studies have evaluated highly
intensive exercise prescription interventions [8,15,16],
and limited evidence supports the hypothesis that more
intensive interventions will lead to larger improvements
in physical fitness and physical activity [8,17]. Further-
more, very few studies have used good measures of aero-
bic fitness and physical activity [18].
In an exercise prescription scheme called 'Exercise on Pre-
scription' (EoP) used in a number of Danish counties GPs
can refer sedentary patients with medically controlled life-
style diseases or risk of developing lifestyle diseases to an
EoP programme. EoP is a highly intensive exercise pre-
scription scheme, which is implemented in primary care
and includes group-based supervised training and motiva-
tional counselling.
The aim of this randomized trial is to assess the short-
(four months) and long-term (ten months) effects of the
highly intensive EoP scheme on physiological variables
(maximal oxygen uptake (VO2max), glycosylated hemo-
globin (HbA1c, in patients with impaired glucose toler-
ance), Body Mass Index (BMI), and bodyweight) and
patient-reported variables (physical activity, health-
related quality of life, amount and intensity of exercise,
compliance with national guidelines for physical activity,
and physical fitness). Thus, the aim of this paper is to
describe the randomized controlled trial designed for
evaluating effectiveness of EoP, and to present results
from validations of outcome measures.
Methods/design
The EoP scheme was evaluated in a randomized trial con-
ducted in 2005–2006 with two groups: EoP and control
patients. The EoP scheme was launched one year prior to
the evaluation and offered by the County of Ribe and the
County of Vejle. Patients were referred to the EoP scheme
by their GP. GPs act as gatekeepers in the Danish health
care system [19].
The motivational counselling and the group-based super-
vised training intervention in EoP patients were carried
out by a physiotherapist in 14 clinics geographically
spread throughout the two counties.
Intervention
Participants randomized to the EoP group followed a
supervised group-based training intervention together
with 8–12 other EoP patients (including patients not tak-
ing part in the trial) (Figure 1). Furthermore, the partici-
pants received motivational counselling (health profiles)
at baseline and after two, four, seven, and ten months
aimed at increasing daily physical activity. The health pro-
files were also used for making a physical activity plan in
collaboration between the physiotherapist and the
patient, and the patient was responsible for the execution
of the plan. During the first two months two weekly 1-
hour training sessions were completed. During the final
two months one weekly 1-hour training session was com-
pleted, totalling 24 training sessions over four months.
The group-based training intervention involved elements
of aerobic conditioning (e.g. Nordic walking and aero-
bics), light strength conditioning (primarily using light
weights and high number of repetitions), stretching, and
games. The physiotherapists were instructed in focusing
on training improving aerobic capacity (more than 50%
of heart rate reserve for a minimum of 20 minutes [20]) in
the majority of training sessions.
Participants randomized to the control group were called
in for a counselling session following randomization (Fig-
ure 1). Furthermore, the control group received similar
health profiles as the EoP group, but only after four and
ten months. After participating in the evaluation the con-
trol group was offered EoP.
Inclusion and exclusion criteria
General practitioners could refer patients with the follow-
ing characteristics: 1) medically controlled lifestyle dis-
eases, 2) motivated to change of lifestyle, 3) believed to be
able to improve health from an increased physical activity
level, and 4) willing to pay 750 DKr. (100 €) for the inter-
vention. In addition to giving the referral the general prac-
titioner informed the patient about the benefits of a
physically active lifestyle in general.Page 2 of 9
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Schematic overview of the randomized trial of 'Exercise on Prescription' (EoP)Figure 1
Schematic overview of the randomized trial of 'Exercise on Prescription' (EoP). The general practitioner (GP) prescribes EoP 
for sedentary patients with medically controlled lifestyle diseases. The patient takes the prescription to an EoP clinic. Patients 
randomized to the EoP group complete five health profiles and a 4-month supervised training intervention. The health profiles 
are completed at baseline, and after two, four, seven, and ten months. The supervised training is organized in groups of 8–12 
EoP patients, and involves many different forms of physical activity. Patients randomized to the control group receive only the 
counselling at baseline, and after four and ten months. After taking part in the trial the control group is offered EoP.
GP prescribes EoP
1st health profile at the EoP clinic
- baseline
Supervised training
- twice a week for two months
Randomization
2nd health profile at the EoP clinic
- two months
Supervised training
- once a week for two months
3rd health profile at the EoP clinic
- four months
4th health profile at the EoP clinic
- seven months
5th health profile at the EoP clinic
- ten months
Motivational counselling
2nd health profile at the EoP clinic
- four months
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Referred patients contacted an EoP clinic, and an appoint-
ment for the first health profile was scheduled (Figure 1).
All patients referred to the EoP scheme were eligible for
the trial and were offered participation in the randomized
trial during the baseline health profile. Recruitment took
place over 14 months in 2005 and 2006.
Informed consent was obtained, and volunteering
patients were randomized to either the EoP group or the
control group. Randomization was carried out by the first
authors by means of concealed envelopes containing the
name of the group. Group allocation was then reported by
mail to the physiotherapist and the patient. Randomiza-
tion was stratified according to diagnosis (cardiovascular
diseases, metabolic syndrome, type II diabetes, and other
diseases) in order to distribute diagnosis groups evenly in
the two groups.
Outcome measures
The EoP physiotherapists carried out both the physiologi-
cal and patient-reported measures. Changes in physiolog-
ical measures (VO2max, bodyweight, BMI, and HbA1c)
and patient-reported measures (physical activity, health-
related quality of life, amount and intensity of exercise,
compliance with national guidelines for physical activity,
and self-reported physical fitness) were assessed at the
time of the health profiles (Figure 1).
Maximal oxygen uptake (VO2max) was measured using a
maximal indirect cycle ergometer test modified from Ped-
ersen & Nielsen [21], where VO2max was calculated from
the maximal work capacity (Wmax). All tests were com-
pleted on a mechanically braked cycle ergometer
(Ergomedic 874E or 828E, Monark, Varberg, Sweden).
Rate of perceived exertion was evaluated using the 6–20
point Borg scale [22]. Heart rate was measured using a tel-
emetric system (Polar Vantage NV, Polar Electro KY, Kem-
pele, Finland). Each workload consisted of three minutes
of cycling at 60 rpm. A choice of two protocols was avail-
able: 1) an initial workload of 30 watts and increments of
30 watts until exhaustion (classic protocol), 2) an initial
workload of 30 watts and increments of 60 watts until the
subject rated perceived exertion ≥ 13 (somewhat hard).
Thereafter increments of 30 watts were used until exhaus-
tion (progressive protocol). The test was continued until
the subject was unable to maintain a pedal frequency of
60 rpm despite verbal encouragement. Workload, maxi-
mal heart rate and total time were recorded, and Wmax
and VO2max were calculated.
Glycosylated hemoglobin (HbA1c) was measured in capillary
blood using the DCA 2000+ (Bayer Diagnostics Europe
Ltd., Dublin, Ireland), and was only assessed in patients
with reduced insulin sensitivity. HbA1c is an indicator of
mean blood glucose level over the last 8–12 weeks and
indirectly a measure of glycemic control [23]. In a com-
parison between DCA 2000+ and the gold-standard tech-
nique in HbA1c assessment the correlation was above 0.9,
and the test-retest reliability with the DCA 2000+ was
above 95 % [24,25].
Bodyweight was measured prior to the cycle ergometer test
with patients wearing light clothes and no shoes using a
commercial scale.
Body Mass Index (BMI) was calculated by dividing body-
weight with height squared.
All patient-reported measures were assessed by means of
self-administered questionnaires distributed by the EoP
physiotherapist during the health profiles. The question-
naire was self-explanatory, easy to fill in, not too exten-
sive, and consisted of preset response categories.
Physical activity was assessed using a short questionnaire,
which allowed for conversion to MET values [26].
Health-related quality of life was assessed using both the SF-
12v2 [27] and EQ-5D [28].
Amount and intensity of exercise were assessed by asking
'how much exercise do you do during an average week?',
and 'at what intensity do you most often exercise?'
Compliance with national guidelines for physical activity was
assessed by asking 'how many days during an average
week are you physically active more than 30 minutes?'
Self-reported physical fitness was assessed by asking 'how do
you rate your present physical fitness?', 'how do you rate
your present physical fitness compared to four months
ago?', and 'how do you rate your present physical fitness
compared to people your age?'
The outcome measures are surrogate measures for reduc-
tion in risk of morbidity and mortality.
All physiotherapists were trained in the different aspects
of the evaluation prior to initiating the randomized trial.
A manual described all parts of the evaluation in detail,
and each clinic was visited several times before and during
the evaluation.
Sample size
Power calculations were performed for expected changes
in VO2max. VO2max at baseline was estimated to 20 ml
O2*(min*kg)-1, expected improvements were 15%, and
expected SD was 3 ml O2*(min*kg)-1. Alpha was set at
0.05 and a power of 0.9 was chosen. Using these assump-Page 4 of 9
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was estimated to 22 in each group.
Statistical analysis
The changes from 0–4 and 0–10 months within the two
groups separately will be assessed using paired t-test or
Wilcoxon rank sum test depending on distribution. Fur-
thermore, boxplots will be made for delta values for the
changes from 0–4 and 0–10 months.
Comparisons between the EoP group and the control
group will be made with changes from 0–4 and 0–10
months. The analysis will be performed as an intention-
to-treat and carried out using a regression model incorpo-
rating delta values, controlling for baseline values, and
adjusted for the effect of the different centres (physiother-
apist clinics), further robust variance will be applied. For
variables not fulfilling the normal distribution of residu-
als a Wilcoxon rank sum test will be used on delta values.
These analyses will be supplemented with 'per protocol
analyses'.
Drop-out analyses will be carried out for 0–4 months and
4–10 months. Completers and non-completers will then
be compared for the different baseline variables using
boxplots. The effect of drop-out will be compared with
differences between the EoP group and the control group.
Statistical significance was set at p < 0.05.
Approval
Local ethics committee registration number VF 20040121.
The Danish Data Protection Agency registration number
2004-41-4692. ClinicalTrials.gov registration number
NCT00399997.
Validation studies
Validation studies were carried out for the cycle ergometer
test, the HbA1c method, and the self-administered ques-
tionnaire. Detailed information about the validation
studies can be found in the appendix.
Wmax cycle ergometer test validation
Validation was performed for both the calculation of
VO2max from Wmax (equation study) and the compari-
son of the two different protocols (protocol study). The
protocol study aimed at finding a less time-consuming
protocol, and evaluating test-retest reliability.
A close relationship between Wmax and VO2max in a
group of EoP patients (Figure 2) and acceptable test-retest
reliability at group level (Figure 3, right) were found. Fur-
thermore, results from the two different protocols were
comparable at group level (Figure 3, left). However, at
individual level the Wmax test was less reliable.
DCA 2000+ glycosylated haemoglobin validation
Test-retest reliability for the DCA 2000+ apparatus was
assessed in healthy subjects. Furthermore, a stability test
of the calibration was performed by checking a DCA
2000+ apparatus with a known standard sample once a
week over a period of ten weeks.
Good test-retest reliability and low LOA over a period of
one week were found. Furthermore, calibration was stable
for a period of ten weeks with minimal use.
Self-administered questionnaire validation
Test-retest reliability for the self-administered question-
naire was assessed for 16 EoP patients, who answered the
questionnaire twice within 1–2 weeks. Agreement
between the two completed questionnaires was assed
using kappa statistics.
The test-retest reliability of the self-administered ques-
tionnaire proved good in terms of agreement percent
despite low kappa values.
Discussion
The EoP trial is designed to provide information about the
effectiveness of the scheme. The trial is part of a health
technology assessment of EoP, which besides the effec-
tiveness covers the patient perspective, the organization,
and the health economy [29].
The validation of the Wmax cycle ergometer test demon-
strated a close relationship between Wmax and VO2max
in a group of EoP patients (Figure 2) and acceptable test-
retest reliability at group level (Figure 3, right). Further-
more, results from the classic and the progressive protocol
were comparable at group level (Figure 3, left). However,
at individual level the Wmax test was less reliable since
LOA between the classic and the progressive test and
between 1st and 2nd test were rather large. The validation
of the DCA 2000+ apparatus for measuring HbA1c
resulted in good test-retest reliability and low LOA in
healthy subjects over a period of one week. Furthermore,
calibration was stable for a period of ten weeks. The test-
retest reliability of the self-administered questionnaire
proved good in terms of agreement percent despite low
kappa values. All three methods were found useful for the
EoP trial.
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Appendix
Wmax cycle ergometer test validation
Subjects were 45 EoP patients (Table 1, top). In the equa-
tion study the test was accepted as a maximal effort if
blood lactate exceeded 8.0 mM and/or respiratory-
exchange-ratio exceeded 1.0. In the protocol study the test
was accepted as maximal effort if maximal heart rate
exceeded 85% of age-predicted maximum (220 minus
age) (Table 1, bottom). Five subjects did not fulfil the cri-
teria and were excluded (three from the equation study
and two from the protocol study), and 40 subjects were
used for the analyses (Table 1, top).
All tests were completed on a mechanically braked cycle
ergometer (Ergomedic 874E or 828E, Monark, Varberg,
Sweden). In the equation study pulmonary gas exchange
was measured breath-by-breath and averaged over the last
30 seconds to determine VO2max (Oxycon Pro, Erich
Jaeger GmbH, Hoechberg, Germany). Blood samples were
collected from a fingertip and analyzed for blood lactate
(YSI 1500 Sport Lactate Analyzer, Yellow Springs Instru-
The Wmax-VO2max relationshipFigure 2
The Wmax-VO2max relationship. The maximal work capacity (Wmax) was plotted against the maximal oxygen uptake 
(VO2max), and linear regression was performed. The relationship was highly linear (VO2max = 13.895 * Wmax + 151 ml O2/
min, R2 = 0.9108, p < 0.0001), but prediction intervals were wide (mean ± 1.96 SD, 452 ml O2/min).Page 6 of 9
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ated using the 6–20 point Borg scale [22]. Heart rate was
measured using a telemetric system (Polar Vantage NV,
Polar Electro KY, Kempele, Finland).
Subjects completed a familiarization test on a separate day
prior to the studies. The equation study used the classic
protocol. The protocol study compared the classic and the
progressive protocols in the protocol study. The classic
Table 1: Cycle ergometer test validation subjects and results. Top: anthropometric data for the subjects. Bottom: results from the 
maximal test. Data are presented as mean ± SD and range.
Equation study Protocol study
Women (N = 10) Men (N = 10) All (N = 20) Women (N = 16) Men (N = 4) All (N = 20)
Age (years) 52 ± 12 52 ± 12 52 ± 11 57 ± 10 53 ± 9 56 ± 10
34–69 26–66 26–69 39–75 40–60 39–75
Weight (kg) 86.9 ± 16.6 99.0 ± 17.0 93.0 ± 17.5 81.9 ± 14.8 97.4 ± 9.3 85.1 ± 14.9
61–105 72–129 61–129 62.9–107.0 88.4–108.7 62.9–108.7
Height (cm) 164 ± 8 178 ± 6 171 ± 10 166 ± 7 178 ± 4 168 ± 8
149–175 172–192 149–192 155–179 174–183 155–183
BMI (kg*m-2) 31.9 ± 4.0 31.1 ± 4.7 31.5 ± 4.3 29.8 ± 4.9 30.7 ± 2.2 30.0 ± 4.3
25.1–37.8 24.2–39.7 24.2–39.7 22.3–36.8 29.2–33.9 22.3–36.8
Heart rate (beats*min-1) 160 ± 15 164 ± 13 162 ± 14 160 ± 16 166 ± 17 160 ± 14
127–179 147–184 127–184 139–185 151–188 139–188
Rate of perceived exertion 18.8 ± 1.2 18.6 ± 1.1 18.7 ± 1.1 18.4 ± 1.1 18.5 ± 1.3 18.5 ± 1.2
17–20 17–20 17–20 16–19 17–20 16–20
Wmax (W) 145.3 ± 36.6 192.7 ± 57.2 169.0 ± 52.7 142.0 ± 36.0 179.3 ± 22.8 149.9 ± 34.6
99.2–215.8 81.7–274.3 81.7–274.3 73–202 156–203 73–203
VO2max (ml O2*min-1) 2,102 ± 455 2,896 ± 827 2,499 ± 767
1,574–3,065 1,285–4,378 1,285–4,378
Respiratory exchange ratio (VCO2max/VO2max) 1.10 ± 0.04 1.06 ± 0.05 1.08 ± 0.05
1.05–1.19 0.99–1.13 0.99–1.19
Differential plots with limits of agreement (LOA) for the classic test vs. the progressive (left) test and 1st test vs. 2nd test (r ght)Fi u  3
Differential plots with limits of agreement (LOA) for the classic test vs. the progressive (left) test and 1st test vs. 2nd test 
(right). The individual differences for the two tests were plotted against the individual mean of the two tests. Furthermore, lim-
its of agreement (LOA) were calculated and plotted (dotted lines). LOA was wide in both comparisons (29.6 watt and 28.6 
watt, respectively), but no statistical significant differences were found. In both cases coefficient of variation was 6.95%.Page 7 of 9
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order and were separated by 3–14 days.
In the equation study linear regression was performed on
the VO2max-Wmax relationship, and a strong correlation
was found (VO2max = 13.895 ml O2*min-1 * Wmax + 151
ml O2*min-1, R2 = 0.911, p < 0.0001) (Figure 2). The pre-
diction interval was 452 ml O2*min-1, which indicated a
large individual variability. Some 95% of observations in
the population are expected to fall within the prediction
interval. The SD used for the prediction interval was the
SD of the difference between measured and estimated
VO2max. In the protocol study the comparison between
the classic and progressive test indicated that the protocols
result in similar Wmax values at group level (Figure 3,
left). Comparison of the 1st and 2nd test found a non-sig-
nificant increase of 3.9 watt (Figure 3, right). However, the
large limits of agreement (LOA) in both comparisons
indicated large individual variability [30]. For this reason
the Wmax test should primarily be used for comparisons
at group level. The coefficient of variation, calculated
using the method of Vasikaran [31], was 6.95% in both
comparisons.
DCA 2000+ glycosylated haemoglobin validation
HbA1c was assessed three times over a period of one week
in nine subjects (four women and five men). Blood sam-
ples were collected from both capillary and vein. Mean
difference of HbA1c between venous and capillary blood
samples was 0.004% HbA1c, and LOA was 0.39. Using
one-way ANOVA resulted in with-in subject SD for the
three time points of 0.13 (LOA 0.26) and 0.16 (LOA 0.32)
for venous and capillary blood, respectively. Only small
variations in the measurement of the standard sample
were observed over a period of ten weeks, and the range of
deviation from the standard samples was 0.1 to 0.4%
HbA1c.
Self-administered questionnaire validation
Agreement was for SF-12 67–97% (mean 90%), for EQ-
5D 69–100% (mean 89%) and for physical activity level
87–99% (mean 93%). However, low kappa values were
found for several questions in SF-12 0.19–0.88 (mean
0.49), EQ-5D 0.25–1.00 (mean 0.66), and physical activ-
ity 0.19–0.91 (mean 0.62), due to an unbalanced mar-
ginal distribution caused by few or no observations in
some response categories and a small number of partici-
pants in this part of the study. The paradox of high agree-
ment percent and low kappa value has been described by
Feinstein and Cicchetti [32].
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